Presentation switch from injectable to microneedle patch formulation

A pharmaceutical company developing a potent biological product in a subcutaneous injectable presentation was co-developing an alternative microneedle patch dosage form in collaboration with a device manufacturer. Chimera assisted in establishing preclinical testing, clinical pharmacology testing and technical specifications for microneedle delivery in preparation for pre-IND meetings with CDER.